Join the Oncology Voice Network. Join for Free
Season 1, Episode 4: Climbing Your Internal Everest with Samuel Blackman

Season 1, Episode 4: Climbing Your Internal Everest with Samuel Blackman


Share This Article


Summary

In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Samuel Blackman, the co-founder and head of R&D at Day One Biopharmaceuticals. Sam shares his experience trekking to Mount Everest Base Camp and the leadership insights he gained from the journey. The conversation covers topics such as vulnerability, facing fears, asking for help, and overcoming obstacles. Sam emphasizes the importance of authenticity and storytelling in leadership and offers recommendations for those seeking personal and professional growth. Overall, the episode provides valuable lessons and inspiration for leaders in the pharmaceutical industry.

In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Samuel Blackman, the co-founder and head of R&D at Day One Biopharmaceuticals. Sam shares his experience trekking to Mount Everest Base Camp and the leadership insights he gained from the journey. The conversation covers topics such as vulnerability, facing fears, asking for help, and overcoming obstacles. Sam emphasizes the importance of authenticity and storytelling in leadership and offers recommendations for those seeking personal and professional growth. Overall, the episode provides valuable lessons and inspiration for leaders in the pharmaceutical industry.

Takeaways:

-Authenticity and vulnerability are essential in leadership, allowing for deeper connections and support among team members.

-Facing fears and asking for help are signs of strength, not weakness, and can lead to personal and professional growth.

-Overcoming obstacles requires examining the situation, identifying what is holding you back, and finding creative solutions.

-Storytelling is a powerful tool in leadership, enabling effective communication and creating emotional connections. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN